Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial - Motzer, Robert J.; Robbins, Paul B.; Powles, Thomas; Albiges, Laurence; Haanen, John B.; Larkin, James; Mu, Xinmeng Jasmine; Ching, Keith A.; Uemura, Motohide; Pal, Sumanta K.; Alekseev, Boris; Gravis, Gwenaelle; et al. (Nature medicine, 2020)
Keywords: 631/67/589/1588/1351; 692/308/53; Adolescent; Adult; Aged; Analysis; Angiogenesis; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antigenic determinants; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Apoptosis; Axitinib; Axitinib - administration & dosage; Axitinib - adverse effects; Biological markers; Biomarkers; Biomarkers, Tumor - genetics; Biomedical and Life Sciences; Biomedicine; Cancer Research; Carcinoma, Renal cell; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - genetics; Carcinoma, Renal Cell - pathology; Care and treatment; Cell death; Development strategies; Drug therapy; Female; Gene expression; Gene Expression Regulation, Neoplastic - drug effects; Humans; Immunomodulation; Immunomodulators; Immunotherapy; Infectious Diseases; Inhibitor drugs; Kidney - drug effects; Kidney - pathology; Kidney cancer; Male; Metabolic Diseases; Middle Aged; Molecular Medicine; Monoclonal antibodies; Neurosciences; Nucleotides; PD-1 protein; PD-L1 protein; Progression-Free Survival; Renal cell carcinoma; Single-nucleotide polymorphism; Sunitinib - administration & dosage; Sunitinib - adverse effects; Targeted cancer therapy; Testing; Transcriptome; Tumors; Young Adult; United States